SOURCE: Arrhythmia Research Technology, Inc.

February 22, 2010 09:30 ET

Arrhythmia Research Technology and Nihon Kohden Sign Multi-Year License Agreement for Predictor™ SAECG Software

FITCHBURG, MA--(Marketwire - February 22, 2010) - Arrhythmia Research Technology, Inc. (the "Company" or "ART") (NYSE Amex: HRT) is pleased to announce it has entered into a multi-year software license agreement with Nihon Kohden Corporation ("Nihon") (TSE: 6849) of Tokyo, Japan. Under the agreement the Company has granted Nihon a non-exclusive and restricted right and license to use, sell and sub-license the Company's proprietary signal-averaging electrocardiography (SAECG) software, PREDICTOR, customized for exclusive use in Nihon's electrocardiogram and other ECG-related products.

James E. Rouse, the Company's President and CEO commented, "We are very pleased to announce that Nihon is the first OEM to license our customizable PREDICTOR SAECG analysis software. This agreement, which has an initial term of five years, is the result of a long and cooperative development project between our two companies. Signal-averaged electrocardiographic analysis is a very valuable risk stratification tool for electrophysiologists and cardiologists in the management of post myocardial infarction patients. ART's PREDICTOR software is considered by the American College of Cardiology and the American Heart Association to be the 'Gold Standard' in signal-averaged electrocardiography analysis. We are very proud that PREDICTOR and the ART name are now associated with Nihon, Japan's largest manufacturer and supplier of medical electronic equipment. Fees associated with this agreement are expected to contribute to revenues beginning in the second quarter of 2010."

A signal-averaged electrocardiogram detects cardiac microvolt signals. Signal averaging, which improves the signal to noise ratio, is a well-recognized technique for detecting and analyzing such cardiac microvolt signals including ventricular late potentials. High resolution acquisition equipment is used to collect the microvolt signals and transfer the data to an analytical system. ART's patented PREDICTOR software filters and analyzes the data to present the signal-averaged ECG for interpretation by a cardiologist.

About Arrhythmia Research Technology, Inc.

The Company's products include proprietary signal-averaging electrocardiography (SAECG) software used in the detection of potentially lethal heart arrhythmias. The Company through its wholly owned subsidiary Micron Products, Inc. manufactures silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG, EEG, EMS and TENS electrodes. Micron's MIT division provides end-to-end product life cycle management through a comprehensive portfolio of value-added services such as design, engineering, prototyping, manufacturing, machining, assembly and packaging. MIT manufactures custom injection molded products for medical, electronic, industrial and consumer applications, and provides high end mold design, manufacturing and precision machining for various industries.

For more information please visit our websites:

http://www.arthrt.com 
http://www.micronproducts.com 
http://www.micronintegrated.com

About Nihon Kohden Corporation
Headquartered in Tokyo, Japan, Nihon Kohden, founded in 1951, is a publicly held company listed in the First Section of the Tokyo Stock Exchange. Nihon Kohden is Japan's leading manufacturer, developer and distributor of patient monitors, defibrillators, electrocardiographs, electroencephalographs, evoked potential and EMG systems, hematology analyzers, and other medical electronic equipment. The company has subsidiaries in the United States, Europe and Asia and distributors in most countries.

For more information please visit: www.nihonkohden.com.

Forward-Looking Statements

Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: our ability to maintain our current pricing model and/or decrease our cost of sales; continued availability of supplies or materials used in manufacturing at competitive prices; volatility in commodity and energy prices and our ability to offset higher costs with price increases; the costs inherent with complying with new statutes and regulations; variability of customer delivery requirements; our ability to efficiently integrate future acquisitions and other new lines of business that the Company may enter in the future. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2008.

Contact Information

  • Contact:
    David A. Garrison
    (978) 345-5000